GW Pharmaceuticals to Present at Upcoming Investor Conferences
September 01 2020 - 7:00AM
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the
Group), a world leader in the science, development, and
commercialization of cannabinoid prescription medicines, today
announced that Justin Gover, GW’s Chief Executive Officer, will
present a business update at the following virtual investor
conferences:
- CITI’s 15th Annual BioPharma
Virtual Conference 2020 on Thursday, September 10th, 2020 at 4:15pm
EDT
- Morgan Stanley Healthcare
Conference 2020 on Tuesday, September 15th, 2020 at 4:15pm EDT
- Cantor Global Healthcare Conference
2020 on Thursday, September 17th, 2020 at 2:40pm EDT
Live audio webcasts of the presentation and
breakout session will be available through GW’s corporate website
at www.gwpharm.com on the Investors section under Events &
Presentations. A replay will be available for each soon after the
live presentation.
About GW Pharmaceuticals plc and
Greenwich Biosciences, Inc.Founded in 1998, GW is a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform in a broad range of disease areas. The Company’s
lead product, EPIDIOLEX® (cannabidiol) oral solution is
commercialized in the U.S. by its U.S. subsidiary Greenwich
Biosciences for the treatment of seizures associated with
Lennox-Gastaut syndrome (LGS), Dravet syndrome or tuberous
sclerosis complex (TSC) in patients one year of age and older. This
product has received approval in the European Union under the
tradename EPIDYOLEX® for the adjunctive treatment of seizures
associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in
conjunction with clobazam in patients two years and older and is
under EMA review for the treatment of TSC. The Company is also
carrying out a Phase 3 trial in Rett syndrome and has a deep
pipeline of additional cannabinoid product candidates, including
nabiximols, for which the Company is advancing multiple late-stage
clinical programs in order to seek FDA approval in the treatment of
spasticity associated with multiple sclerosis and spinal cord
injury, as well as for the treatment of PTSD. The Company has
additional cannabinoid product candidates in Phase 2 trials for
autism and schizophrenia. For further information, please visit
www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc |
|
Stephen Schultz, VP Investor Relations (U.S.) |
917 280 2424 / 401 500 6570 |
|
|
|
|
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Apr 2023 to Apr 2024